Metastatic Colorectal Cancers Active Not Recruiting Phase 2 Trials for Irinotecan (DB00762)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01298570Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal CancerTreatment
NCT03142516FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance StatusTreatment
NCT03164655SULTAN (Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network)Treatment
NCT02292758Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by SurgeryTreatment
NCT02497157Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal CancerTreatment
NCT02624726Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line TreatmentTreatment
NCT01328171FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)Treatment
NCT01867697Nordic 8 - A Phase II TrialBasic Science
NCT02296203Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).Treatment